EGFR and neoplasm: As of 2024, osimertinib is currently approved in the adjuvant setting in patients with exon 19 deletions or L858R mutations treated with tumor resection, in the first line setting in patients harboring exon 19 deletions or L858R mutations either as monotherapy or in combination with pemetrexed or platinum-based chemotherapy, or in the second-line setting in patients who progressed on previous EGFR TKI therapies who harbor the T790M resistance mutation [27].